PrEP (HIV Pre-Exposure Prophylaxis)Features

And Then There Were Two: FTC/TAF Is Also PrEP

#3 in TheBodyPro's Top 10 HIV Clinical Developments of 2019

F/TAF for PrEP photo illo
Photo illustration: Remedy Health Media; Background and paper tear: iStock

    DISCOVER 48-week results: 26th Conference on Retroviruses and Opportunistic Infections. (2019). "The phase 3 DISCOVER Study: Daily F/TAF or F/TDF for HIV preexposure prophylaxis."

    DISCOVER 96-week results: 17th European AIDS Conference. (2019). "Phase 3 randomized, controlled DISCOVER study of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis: week 96 results."

    David Alain Wohl, M.D.

    David Alain Wohl, M.D.

    David Alain Wohl, M.D., is a professor at the University of North Carolina, site leader of the UNC AIDS Clinical Trials Unit at Chapel Hill, director of the North Carolina AETC, and co-director of HIV services for the NC state prison system.